JNM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH RSS TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


First published online November 7, 2008, 10.2967/jnumed.108.053934
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
jnumed.108.053934v1
49/12/2026    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in JNM
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Eterovic, D.
Right arrow Articles by Grosev, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Eterovic, D.
Right arrow Articles by Grosev, D.
Journal of Nuclear Medicine Vol. 49 No. 12 2026-2030
© 2008 by Society of Nuclear Medicine

doi: 10.2967/jnumed.108.053934

Brief Communication

Planning of 131I Therapy for Graves Disease Based on the Radiation Dose to Thyroid Follicular Cells

Davor Eterovic1,2, Zeljko Antunovic3, Vinko Markovic1 and Darko Grosev4

1 Department of Nuclear Medicine, University Hospital Split, University of Split Medical Faculty, Split, Croatia; 2 Department of Medical Physics, University Hospital Split, University of Split Medical Faculty, Split, Croatia; 3 Department of Physics, Faculty of Mathematics and Natural Sciences, University of Split, Split, Croatia; and 4 Clinical Department of Nuclear Medicine and Radiation Protection, Clinical Hospital Center Zagreb, Zagreb, Croatia

Correspondence: For correspondence or reprints contact: Davor Eterovic, Department of Medical Physics, Medical Faculty Split, Soltanska 2, 21000 Split, Croatia. E-mail: eterovic{at}bsb.mefst.hr

We evaluated the effects on the absorbed dose to thyroid follicular cells of self-absorption of 131I radiation (specifically, β-rays) in the follicular colloid. Methods: Thyroid follicles were modeled as colloid-filled spheres, containing a uniform concentration of 131I and surrounded by a concentric monolayer of cells. Assuming close packing of identical follicles, we used Monte Carlo simulation to assess the absorbed dose to follicular cells. Results: Because of β-ray self-absorption in colloidal spheres with radii larger than 50 µm, the absorbed dose to follicular cells is less than the average thyroid absorbed dose. Conclusion: For the same thyroid mass, radioiodine thyroid uptake, and effective half-life, patients with follicles with colloidal sphere radii of 100, 200, 300, and 400 µm should be administered 9%, 15%, 21%, and 30% more 131I, respectively, than patients with colloidal sphere radii of less than 50 µm, to yield the same absorbed dose to follicular cells.

Key Words: Monte Carlo • diffuse toxic goiter • absorbed dose • echogenicity • thyroid follicle

COPYRIGHT © 2008 by the Society of Nuclear Medicine, Inc.


Related articles in JNM:

This Month in JNM

JNM 2008 49: 11A-12A. [Full Text]  



This article has been cited by other articles:


Home page
JNMHome page
D. Eterovic, V. Markovic, A. Punda, and Z. Antunovic
131I Radiation Dose Distribution in Metastases of Thyroid Carcinoma
J. Nucl. Med., May 1, 2009; 50(5): 833 - 834.
[Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH RSS TABLE OF CONTENTS
JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY THE JOURNAL OF NUCLEAR MEDICINE
Copyright © 2008 by the Society of Nuclear Medicine.